The FDA accepted the Anaphylm NDA resubmission as a class 2 response, setting a March 16, 2027, PDUFA date for the sublingual epinephrine film.
News|Videos|March 12, 2025
RX Review: The role of needle-free epinephrine in pediatric allergy for 2025
In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management.
Advertisement
Advertisement
In this Contemporary Pediatrics and HCPLive RX Review discussion, moderator Brian Schroer, MD, speaks with Colleen Kraft, MD, and Russell Traister, MD, about the impact of needle-free epinephrine options, including epinephrine nasal spray (neffy) which received approval for treating type 1 allergic reactions in patients aged 4 years and older weighing at least 30 kg on March 5, 2025.1
Related to this article
In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.
Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
FDA approves berotralstat 150-mg oral pellets for HAE prophylaxis in patients 12+ who cannot or prefer not to swallow capsules.
Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.
Black race was the strongest predictor of T2-high inflammation in 451 children with severe asthma adjusted for social and environmental factors.
In phase 3 SHINE-2, 50% of mirikizumab induction responders aged 6 to 17 with moderate to severe UC were in clinical remission at week 52.
Advertisement
Advertisement